Your Search Results

DCB - Going beyond in-stent restenosis

20 May 2026 – From EuroPCR 2026

This session examines the expanding role of drug-coated balloons (DCB) beyond in-stent restenosis, including treatment of acute coronary syndromes, calcified lesions, and bifurcations. It reviews current evidence supporting DCB-based revascularization and outlines essential procedural steps to optimize outcomes.

Prognostics elements on multivessel disease and coronary artery disease

20 May 2026 – From EuroPCR 2026

This session examines key prognostic elements in multivessel and coronary artery disease, featuring studies on mechanical circulatory support across LDL-C levels, biomarkers impacting periprocedural myocardial infarction, autologous cell therapy outcomes for refractory angina, and novel risk stratification indices. It also addresses prognosis in cancer patients and...

Reliability and application of angio-based physiology in daily work

20 May 2026 – From EuroPCR 2026

This session evaluates the reliability and clinical application of angiography-based physiological assessments in daily practice. Topics include comparisons of angiography-derived microvascular resistance and flow metrics with invasive methods, reproducibility of quantitative flow ratio (QFR), and its correlation with symptom burden and other imaging modalities.

Lost, crushed, fractured: stent complications in real life

20 May 2026 – From EuroPCR 2026

This session addresses real-world challenges of stent complications including loss, crushing, and fracture during PCI. Through case-based discussions, it explores complex scenarios such as stent dislodgement, embolisation, and management strategies when initial plans evolve into complicated realities.

$Lost, crushed, fractured: stent complications in real life$

Frequency and safety of bioprosthetic valve fracture in patients undergoing valve in valve TAVR for failed surgical valves using the SAPIEN 3/Ultra Valves: Insights from real-world data

19 Sep 2022

Michele Pighi provides his take on this trial which aimed to compare the safety and efficacy of VIV-TAVI with or without bioprosthetic valve fracture. It was presented by Santiago Garcia during the TCT Congress 2022.